Refine by
Vaccine For Covid Articles & Analysis
120 news found
The project has the goal to develop a “Pan-protective SARS-CoV-2 vaccine” hoping to show protection against all past and future variant of concern of the Corona virus. ...
Their pioneering research has revolutionized the way we combat infectious diseases and has undoubtedly saved countless lives during the COVID-19 pandemic." In effect, mRNA vaccines have reached the spotlight for a while as a new alternative to conventional vaccines. ...
The notable additions to Alfa Chemistry's IVD product portfolio are: COVID-19 Mutation RT-qPCR Detection Kit, COVID-19 RT-qPCR Detection Kit Plus, and COVID-19 RT-qPCR Detection Kit (RUO). ...
Emalfarb concluded. “The COVID-19 pandemic brought mRNA technology to the forefront, showing its potential to prevent and treat diseases. ...
"End-to-End Support for Your Pharmaceutical Journey", with the commitment to researchers, BOC Sciences will attend the renowned World Vaccine Congress Europe in Barcelona, Spain, from 16 to 19 Octobe World Vaccine Congress Europe has become the world's largest and most established meeting dedicated to vaccines. ...
HM King Philippe and HM Queen Mathilde, currently on a state visit to South Africa until March 27, visited the Afrigen Biologics facility in Cape Town to learn more about how two Belgian companies, Univercells and etherna, are supporting the development of the first African- developed mRNA COVID-19 vaccine. The King and The Queen are accompanied by five ...
ByeTheRNA
Challenges in viral vaccine manufacturing: “The product is the process” In the vaccine field, “the product is the process”. ...
ByNuvonis
With support from NSF, we will be working toward our mission and addressing the rapid escalation of the COVID-19 pandemic by optimizing combinations and dosing strategies of FDA approved drugs as a repurposed, multi-targeted approach against COVID-19. Vaccination and single therapies continue to scale around the world but we strongly believe our ...
As founding Chief Scientific Officer (CSO) at Moderna Therapeutics, he pioneered modified mRNA as a new therapeutic and vaccine drug modality and the mRNA chemistry and delivery systems that form the basis of the approved COVID-19 mRNA vaccines. ...
ByeTheRNA
Analysis by Airfinity shows between 1.3 and 2.1 million lives could be at risk if China lifts its zero-COVID policy given low vaccination and booster rates as well as a lack of hybrid immunity. ...
IRVINE, Calif. – OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). The publication, titled “Enhanced Progression-Free Survival in ...
Airfinity predicts a potential ‘twindemic’ of COVID-19 and flu could overwhelm hospitals this winter. The analysis focuses on two potential scenarios, based on data from previous winter COVID-19 waves driven by the Alpha and Omicron BA.1 variants as well as historical flu admissions from 2017-2018, the last bad flu season, as another bad flu season is expected this year based on ...
Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. This includes Pfizer/BioNTech for COMIRNATY, which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries. ...
With an expanded portfolio and increasing technical, regulatory, and market challenges for COVID-19 vaccine development, we have decided not to proceed with an IND submission for IBIO-202, our multi-variant COVID-19 vaccine candidate. ...
The granted R&D project is 'Development of sublingual COVID-19 subunit vaccine,' in which CHA Vaccine Institute, PanGen Biotech, and BioLingus will develop a sublingual tablet or drop type of recombinant subunit COVID-19 vaccine. ...
The results were published in the article “A Personal COVID-19 Dendritic Cell Vaccine Made at Point-of-Care: Feasibility, Safety, and Antigen-Specific Cellular Immune Responses” in the journal Human Vaccines & Immunotherapeutics. ...
Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. This includes Pfizer/BioNTech for COMIRNATY, which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries. ...
Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. ...
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially ...
Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. This includes Pfizer/BioNTech for COMIRNATY, which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other ...